[![LegislationCrest](/images/crests/ukpga.gif)](/ukpga/2016/9/introduction/enacted?view=plain), 
# Access to Medical Treatments (Innovation) Act 2016, 
# 2016 CHAPTER 9, 
An Act to make provision for access to innovative medical treatments; and forconnected purposes., 
[23rd March 2016], 
Be it enacted by the Queen’s most Excellent Majesty, by and with the adviceand consent of the Lords Spiritual and Temporal, and Commons, in this presentParliament assembled, and by the authority of the same, as follows:—, 
## Introductory, 
### 1Access to innovative medical treatments, 
The purpose of this Act is to promote access to innovative medical treatments(including treatments consisting in the off-label use of medicines or the useof unlicensed medicines) by providing for—, 
(a)the establishment of a database of innovative medical treatments, and, 
(b)access to information contained in the database., 
## Database of innovative medical treatments, 
### 2Database of innovative treatments, 
(1)The Secretary of State may by regulations make provision conferringfunctions on the Health and Social Care Information Centre (“the HSCIC”) inconnection with the establishment, maintenance and operation of a databasecontaining information about—, 
(a)innovative medical treatments carried out by doctors in England, and, 
(b)the results of such treatments., 
(2)In this section, “innovative medical treatment” means medical treatment fora condition that involves a departure from the existing range of acceptedmedical treatments for the condition., 
(3)Regulations under subsection (1) may in particular—, 
(a)confer power on the HSCIC to make provision about—, 
(i)the information to be recorded in the database, and, 
(ii)procedures relating to the recording of information in the database;, 
(b)make provision for and in connection with access to information recorded inthe database., 
(4)The provision that may be made by virtue of subsection (3)(b) includes, inparticular—, 
(a)provision requiring or authorising the HSCIC to disclose information—, 
(i)to specified persons or descriptions of person, or, 
(ii)for use for specified purposes;, 
(b)provision requiring or authorising the HSCIC to impose conditions to becomplied with by persons to whom information is disclosed by virtue ofparagraph (a) (which may include conditions restricting the use or furtherdisclosure of information)., 
(5)Regulations under subsection (1) may be made in relation to innovativemedical treatments generally or innovative medical treatments falling within aspecified description., 
(6)Before making regulations under subsection (1) the Secretary of State mustconsult the HSCIC., 
(7)In this section, “specified” means specified in regulations undersubsection (1)., 
(8)The power to make regulations under subsection (1) is exercisable bystatutory instrument; and an instrument containing such regulations is subjectto annulment in pursuance of a resolution of either House of Parliament., 
### 3Section 2: supplementary, 
(1)In section 2, “doctor” means a registered medical practitioner., 
(2)For the purposes of section 2(2), the kinds of medical treatment that maybe innovative medical treatments include (amongst other things)—, 
(a)the off-label use of an authorised medicinal product, and, 
(b)the use of a medicinal product in respect of which no marketingauthorisation is in force., 
(3)In subsection (2)(a), the reference to the off-label use of an authorisedmedicinal product is a reference to the use of the product—, 
(a)for a purpose other than one for which its use is specified,, 
(b)in relation to a person who is not within a description of persons for whomits use is specified, or, 
(c)in any other way in which its use is not specified., 
(4)In this section—, 
(a)“authorised medicinal product” means a medicinal product in respect ofwhich a marketing authorisation is in force;, 
(b)“marketing authorisation” and “medicinal product” have the same meanings asin the Human Medicines Regulations 2012 ([S.I.2012/1916](/id/uksi/2012/1916?view=plain "Go to item of legislation"));, 
(c)“specified”, in relation to a medicinal product, means specified in itsmarketing authorisation., 
(5)References in section 2 to medical treatment include references totreatment carried out for the purposes of medical research (but nothing insection 2 is to be read as affecting the regulation of medical research)., 
(6)Nothing in section 2 applies in relation to treatment which is carried outsolely for cosmetic purposes., 
## Final, 
### 4Extent, commencement and short title, 
(1)This Act extends to England and Wales only., 
(2)Sections 1, 2 and 3 come into force on such day or days as the Secretary ofState may by regulations made by statutory instrument appoint., 
(3)Regulations under subsection (2) may—, 
(a)appoint different days for different purposes;, 
(b)make transitional or saving provision., 
(4)This section comes into force on the day on which this Act is passed., 
(5)This Act may be cited as the Access to Medical Treatments (Innovation) Act2016., 
